Tooth whitener safety
This article was originally published in The Tan Sheet
Executive Summary
Canadian researchers determine tooth-whitening products with hydrogen peroxide or carbamide peroxide do not increase users' risks for oral cancers, including people who abuse alcohol and/or are heavy smokers. The review of study literature, including unpublished studies with tests involving more than 4,000 people, was conducted by Ian Munro, PhD, associate director of the University of Toronto's Program in Food, Safety & Regulatory Affairs, et al., and published in the Journal of Esthetic & Restorative Dentistry, according to a Nov. 16 release. Exposures to hydrogen peroxide, which generally is the effective ingredient in tooth whiteners, are too low and, at 30 to 60 minutes, too brief to increase risks for oral cancer, the study results show. Concentrations of the substance quickly diminish to be nearly undetectable within 15 to 60 minutes. In March 2005, a European Union's Scientific Committee on Consumer Products 1opinion raised concerns about the safety of products containing the ingredients. In Europe, tooth whitening products with hydrogen peroxide or carbamide peroxide are only available to consumers from a dental practitioner, Munro et al. note...
You may also be interested in...
Shine More Safety Data On Tooth Whiteners With Hydrogen Peroxide – SCCP
The use of oral hygiene products and tooth whitening products containing more than 0.1 percent hydrogen peroxide cannot be deemed safe in the absence of long-term clinical data assessing possible adverse effects within the oral cavity, the European Commission's science panel says
As Casgevy, Lyfgenia Launches Proceed, CRISPR And bluebird bio CEOs Reassure
The CEOs of bluebird bio and CRISPR Therapeutics hope to inspire investor confidence that their gene-based therapies for sickle cell disease and beta thalassemia will be widely reimbursed in the US and EU.
Japan Regulatory Update: Revised Law Widens RWD Scope, Price Revisions/Listings
Japan now allows pseudonymized personal data for medical use under a licensing system for wider use of real-world data. Meanwhile, a national cost-effectiveness assessment scheme has slashed reimbursement prices for Lagevrio and Kerendia, and Alexion’s Voydeya has been added to the reimbursement tariff.